RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.
- DOI
- 10.1371/journal.pone.0277706
- Published
- 2022-11-15
- Container
- PLoS One
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
serious concern Score 18/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1371/journal.pone.0277706,
title = {RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.},
author = {Grobbee EJ and de Jong VD and Schrieks IC and Tushuizen ME and Holleboom AG and Tardif JC and Lincoff AM and Schwartz GG and Castro Cabezas M and Grobbee DE.},
year = {2022},
journal = {PLoS One},
doi = {10.1371/journal.pone.0277706},
url = {https://doi.org/10.1371/journal.pone.0277706}
}RIS
TY - JOUR TI - RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar. AU - Grobbee EJ AU - de Jong VD AU - Schrieks IC AU - Tushuizen ME AU - Holleboom AG AU - Tardif JC AU - Lincoff AM AU - Schwartz GG AU - Castro Cabezas M AU - Grobbee DE. PY - 2022 JO - PLoS One DO - 10.1371/journal.pone.0277706 UR - https://doi.org/10.1371/journal.pone.0277706 ER -
APA
EJ, G., VD, D. J., IC, S., ME, T., AG, H., JC, T., AM, L., GG, S., M, C. C., & DE., G. (2022). RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.. PLoS One. https://doi.org/10.1371/journal.pone.0277706
Source records
- europe-pmc · retrieved 2026-09-25T00:24:46.912Z
- doaj · retrieved 2026-09-25T00:24:46.898Z